Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identi®ed in a proportion of melanoma kindreds. In the case of CDK4, only one speci®c mutation, resulting in the substitution of a cysteine for an arginine at codon 24 (R24C), has been found to be associated with melanoma. We have previously reported the identi®cation of germline CDKN2A mutations in 7/18 Australian melanoma kindreds and the absence of the R24C CDK4 mutation in 21 families lacking evidence of a CDKN2A mutation. The current study represents an expansion of these eorts and includes a total of 48 melanoma families from Australia. All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1b) of CDKN2A. Families lacking CDKN2A mutations, but positive for a polymorphism(s) within this gene, were further evaluated to determine if their disease was associated with transcriptional silencing of one CDKN2A allele. Overall, CDKN2A mutations were detected in 3/30 (10%) of the new kindreds. Two of these mutations have been observed previously: a 24 bp duplication at the 5' end of the gene and a G to C transversion in exon 2 resulting in an M53I substitution. A novel G to A transition in exon 2, resulting in a D108N substitution was also detected. Combined with our previous ®ndings, we have now detected germline CDKN2A mutations in 10/48 (21%) of our melanoma kindreds. In none of the`CDKN2A-negative' families was melanoma found to segregate with either an untranscribed CDKN2A allele, an R24C CDK4 mutation, a CDKN2B mutation, or an E1b mutation. The last three observations suggest that these other cell cycle control genes (or alternative gene products) are either not involved at all, or to any great extent, in melanoma predisposition.
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Keywords: CDKN2A; CDKN2B; CDK4; melanoma; familial; mutation The CDKN2A (or p16) gene is located on chromosome 9p21 within a region that has been found to be frequently deleted in sporadic melanomas Holland et al., 1994; Isshiki et al., 1994; Kamb et al., 1994a; Nobori et al., 1994; Ohta et al., 1994 Ohta et al., , 1996 Walker et al., 1994; Luca et al., 1995; Platz et al., 1996; Flores et al., 1996) and is genetically linked to familial melanoma (Cannon-Albright et al., 1992; Nancarrow et al., 1993; Gruis et al., 1993 Gruis et al., , 1995a Goldstein et al., 1994; MacGeoch et al., 1994; Holland et al., 1995) . p16 is a pivotal cell cycle regulator that binds to the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) and inhibits their ability to phosphorylate the retinoblastoma protein (pRb) (Serrano et al., 1993) . Loss (or reduction in the amount) of p16 in a cell (a melanocyte, in this case) presumably augments cell division by releasing à brake' that exists between the G1 to S phase of the cell cycle. The CDKN2A gene has been shown to ful®ll the requirements of a classical tumor suppressor gene (Knudson, 1971) , where inactivation of both alleles has been detected frequently in tumor cell lines (Nobori et al., 1994; Kamb et al., 1994a; Hussussian et al., 1994; Liu et al., 1995a; Luca et al., 1995; Pollock et al., 1995 Pollock et al., , 1996 Ohta et al., 1994; Flores et al., 1996) and, to a lesser extent, in uncultured tumors (Gruis et al., 1995b; Ohta et al., 1996; Platz et al., 1996; Flores et al., 1996) from familial and sporadic melanoma patients.
Approximately 50% of all familial melanoma kindreds have been found to be genetically linked to markers located within the 9p21 region (CannonAlbright et al., 1992; Nancarrow et al., 1993; Gruis et al., 1993 Goldstein et al., 1994; MacGeoch et al., 1994; Holland et al., 1995) . Though germline mutations have been detected in the CDKN2A gene in many of these kindreds, disparate results between studies suggest that CDKN2A may not be the only melanoma predisposition locus within this region (for review, see Dracopoli and Fountain, 1996) . The detection of CDKN2A mutations in 11/13 unrelated 9p21-linked families from the NIH provides the strongest evidence in support of this gene being the only familial melanoma locus on 9p (Hussussian et al., 1994; Goldstein et al., 1995) . Similarly, we have also detected CDKN2A mutations in 7/18 (39%) of our melanoma kindreds (both 9p21-linked and unlinked) from Australia . In contrast, other analogous studies have failed to identify a high frequency of CDKN2A mutations, even where large numbers of melanoma kindreds were analysed (Kamb et al., 1994b; MacGeoch et al., 1994; Ohta et al., 1994; Gruis et al., 1995c (views 13 families with a common founder as one); Holland et al., 1995; Liu et al., 1995b; Borg et al., 1996; Fitzgerald et al., 1996; Platz et al., 1997) .
Evidence of locus heterogeneity has been demonstrated previously in genetic linkage studies performed on familial melanoma (Goldstein et al., 1993 MacGeoch et al., 1994) . The recent identi®cation of germline mutations within the CDK4 gene on chromosome 12q15 that cosegregated with melanoma in two NIH families (Zuo et al., 1996) now provides proof that more than one melanoma predisposition gene exists within the genome. The ®nding of the same CDK4 mutation (resulting in a cysteine substitution for an arginine at codon 24; abbreviated R24C) in both of these families, as well as its occurrence as a somatic alteration in two sporadic melanomas (WoÈ lfel et al., 1995) , suggests that this may be the only CDK4 mutation that is relevant to melanoma predisposition or tumorigenesis. This mutation has also been shown to functionally disrupt the binding of p16 (and p15) to CDK4, while the binding of other cyclin-dependent kinase inhibitors to CDK4 remains unaltered (WoÈ lfel et al., 1995) .
Additional potential candidate genes for involvement in familial melanoma include the CDKN2B (or p15) gene, which is a CDKN2A homolog that resides 535kb proximal to CDKN2A on 9p21 (Kamb et al., 1994a; Hannon and Beach, 1994) , and an alternative gene product, encoding another cell cycle inhibitor (ARF), produced at the CDKN2A locus (Stone et al., 1995a; Mao et al., 1995; Quelle et al., 1995) . The CDKN2B gene is an obvious candidate gene for melanoma predisposition both due to its location and its high homology to the CDKN2A gene. Inactivation of this gene has also been observed either (at a high frequency) along with the CDKN2A gene (Kamb et al., 1994a; Flores et al., 1996) , or (at a low frequency) independent of the CDKN2A gene (Stone et al., 1995a; Glendening et al., 1995; Flores et al., 1996) in sporadic melanoma tumors and cell lines. Similarly, the ARF (alternative reading frame) protein, which is produced from a transcript composed of a dierent exon 1 (E1b) spliced to exons 2 and 3 of the CDKN2A gene, is also consistently disrupted in sporadic melanomas and, while bearing little or no resemblance to the p16 or p15 proteins, is another potent inhibitor of cell cycle progression that functions independent of the CDKs (Quelle et al., 1995) .
The current study was aimed at determining the overall frequency of CDKN2A (including the ARF product), CDKN2B, and CDK4 mutations in 48 melanoma kindreds from Australia. The 9p21 linkage and mutational status for CDKN2A in 18 families and for CDK4 (speci®cally the R24C mutation) in 21 families has already been reported (Nancarrow et al., 1993; Walker et al., 1994 Walker et al., , 1995 Zuo et al., 1996) . Thus, our mutational screens (using single-strand conformation polymorphism (SSCP), followed by direct DNA sequencing) of CDKN2A and CDK4 were con®ned to 30 and 27 of the families, respectively, while all CDKN2A-negative' families (a total of 38) were analysed for mutations in ARF and CDKN2B. Additional analyses were also performed to determine if any of our new melanoma kindreds (n=30) showed evidence of linkage to 9p21 and, when possible, if melanoma segregated with a silent (untranscribed) CDKN2A allele in families determined to be negative for a mutation within CDKN2A.
9p21 linkage/haplotype analysis Lymphoblastoid DNAs from available members of the 30 new Australian melanoma families (some pedigree and background information provided in Nancarrow et al., 1993; Walker et al., 1994 Walker et al., , 1995 others are unpublished) were initially analysed with 9p21 microsatellite markers (e.g., IFNA, D9S942, D9S171, and D9S126) to determine the likelihood of linkage to 9p. Haplotypes were constructed and then used to group aected cases (where indicated) with a common 9p haplotype. Only 8/30 of the families (41119, 41109, 40594, 41095, 41102, 41112, 40999, 41096) were found to have aected members that all shared the same haplotype and were, therefore, assumed to be the families with the highest likelihood of inheriting a mutation within the CDKN2A gene ( Table 1 ). The remaining 22 families were deemed`indeterminant' for linkage to 9p21 since one to three of the aected cases in each of these families did not share the same 9p haplotype. If some of these latter families are actually linked to 9p, then the non-segregating individuals with melanoma in these families are presumed to be sporadic cases.
CDKN2A mutations and polymorphisms SSCP and DNA sequencing analyses were performed on exons 1a, 2, and 3 of the CDKN2A gene as previously described . Three mutations were identi®ed after examining one (in some families with a shared 9p21 haplotype) or more aected members from each of the 30 new families. Only one (family 41119) out of eight of the families initially presumed by segregation analysis to be a likely carrier for a CDKN2A mutation was positive for a mutation (Table 1) . In this case, all ®ve of the aected individuals genotyped from this family were found to carry a 24 bp repeat mutation present at the 5' end of the original exon 1 (E1a) of the CDKN2A gene (Table 1 and Figure 1a) . The other two mutations were both in exon 2 and were detected in two of the`9p-indeterminate' families (41031 and 41105). The mutation in family 41031, a G to C transversion at nucleotide position 159, resulting in a M53I substitution in p16, was identi®ed in 2/3 of the aected individuals analysed from this family (Table 1 and Figure 1b) . The last mutation, a novel G to A transition at nucleotide position 322, resulting in a D108N substitution in p16, was detected in 2/4 aected members from family 41105 (Table 1, Figure 1c and Figure 2 ).
Both the 24 bp duplication and the M53I substitution have been reported previously by ourselves , as well as by others (reviewed in Dracopoli and Foulkes et al., 1997; Fitzgerald et al., 1996) . The detection of these same mutations in independent studies suggests that either (i) there are mutational`hotspots' within the CDKN2A gene, or (ii) the families collected in these studies are related through ancestry. A comparison of haplotypes between thè 24 bp duplication' or`M53I' families suggests the latter is the case and that these families may descend from a limited number of founders (P Pollock et al., manuscript submitted). The recurrent identi®cation of these two mutations in melanoma kindreds, and not in unaected individuals within the general population, implies they are indeed responsible for the increased incidence of melanoma in these families. While the third mutation, a D108N substitution, has not been reported previously in any other melanoma kindreds, it has, similarly, only been identi®ed in individuals aected with melanoma and is, therefore, presumed to have a deleterious eect on the p16 protein.
All other SSCP variants identi®ed in these 30 families were determined to result from three established polymorphisms within the CDKN2A gene. Two of these polymorphisms reside in exon 2 (both G to A transitions at nucleotide positions 318 and 442, respectively), while the third, a C to G transversion at nucleotide 500, resides in the 3' untranslated region of exon 3 (reviewed in Pollock et al., 1996) . Table 2 shows a compilation of the CDKN2A polymorphisms detected in all 48 of the families. Overall, one family (41015) was positive for the polymorphism at nucleotide position 318 (see also Figure 2) , four carried the G to A transition at position 442, and 16 were positive for the C to G transversion at nucleotide 500.
Transcription of CDKN2A alleles
The identi®cation of polymorphisms within exons 2 and 3 of the CDKN2A gene aorded us the opportunity to distinguish between CDKN2A alleles in 11 families that had been deemed non-mutant, but were polymorphic, for CDKN2A (Table 2) . Speci®cally, we were interested in determining if transcriptional silencing of a CDKN2A allele cosegregated with melanoma in these families. This was assessed by reverse transcribing RNA isolated from lymphoblastoid cell lines (LCLs) derived from appropriate (i.e. aected and heterozygous) family members, followed by PCR ampli®cation and sequencing of products that contained both the nucleotide 442 (in exon 2) and 500 (in exon 3) polymorphic sites. Theoretically, this assay served as a gross screen for promoter mutations that might aect the transcription of a CDKN2A allele or, alternatively, could indicate transcriptional silencing of a CDKN2A allele via DNA methylation or imprinting. In no instance was loss of expression of either CDKN2A allele observed in any of these 11 families (data not shown).
ARF mutation screen
All families determined to be negative for mutations within the`original' CDKN2A coding/promoter sequences were screened by SSCP for mutations Nucleotide and codon numbering for CDKN2A have been modi®ed from Serrano et al. (1993) ; the corrected numbering system alters the`original' nucleotide positions by six and amino acid codons by eight. For example, the G to C transversion at nucleotide position 153, previously designated as a M45I substitution in p16 , is now referred to as a mutation at nucleotide position 159 and is a M53I substitution. Primer sequences used to analyze E1b were 5'-CACCTCTGGTGCCAAAG-3' (forward primer) and 5'-CAAAACAAGTGCCGAATGCG-3' (reverse primer). Families in which all aected cases shared a common 9p21 haplotype. e Twenty-four base pair insertion, representing the additional copy of a 24 bp repeat naturally present as two copies at the 5' end of the CDKN2A gene; predictably, this mutation leads to the insertion of an additional eight amino acids (a.a.) at the N terminus of p16 (see Walker et al., 1995 for a more detailed description) within the alternative exon 1 (E1b) using similar methods as for exon 1a . No variant SSCP bands were observed on any of the individuals analysed from these families, indicating that melanoma predisposition mutations, as well as benign polymorphisms, are rare (or non-existent) within this exon of CDKN2A. Three other groups have also reported a similar lack of exon 1b mutations in their melanoma kindreds, implying that this alternative CDKN2A product is not involved in melanoma predisposition (Stone et al., 1995a; Fitzgerald et al., 1996; Platz et al., 1997) . It should be noted, however, that a proportion of the mutations identi®ed in exon 2 of the CDKN2A gene also aect the protein translated from the ARF transcript. For example, the G to A transition at nucleotide position 322 (associated with the D108N substitution in family 41119) produces a signi®cant change (arginine for glutamine) in ARF (Table 1) . Likewise, the G to C transversion at nucleotide position 159, associated with the M53I substitition in p16, changes a negatively-charged amino acid (aspartic acid) to a positively charged one Figure 1 Pedigree structures of families incorporating results of 9p21 haplotype and CDKN2A mutation analyses. Individual identi®cation numbers are shown beneath each pedigree symbol and age of onset of melanoma or age at last contact is given above each symbol. Pedigrees have been condensed to conserve space and preserve a degree of anonymity. (a) Family 41119: all aecteds analysed share a common (boxed) haplotype which cosegregates with a 24 bp duplication (+ ins) in exon 1a of the CDKN2A gene and melanoma. (b) Family 41031: individuals 001 and 005 are carriers of a missense mutation associated with a M531 substitution in p16. The three other individuals analysed in this pedigree are wild-type (wt) at the CDKN2A locus. An asterisk represents an inferred haplotype from individual 001 inherited from his decreased father; haplotype analysis was not performed on 005. A more extensive number of markers was typed in this family to determine that the aected individual 002 did not share the same CDKN2A (disease) allele as 001. The location of CDKN2A is indicated by an arrow and the boxed regions in 002 and 004 mark haplotypes that are partially shared with 001. Individual 002 is presumed to be a sporadic case of melanoma. (c) Family 41105: individuals 001 and 002 carry a mutation which is associated with a D108N substitution in p16, whereas the remaining family members analysed (regardless of disease status) were determined to be wild type (wt) for CDKN2A. The`disease' haplotype is indicated by either solid or dashed boxes; unable to conclusively assign in this pedigree. The presumed sporadic occurrence of melanoma in a 19 year old individual (006) in this family also illustrates the necessity to dermatologically screen all individuals in a kindred regardless of mutational status at the CDKN2A locus. This discovery suggests that other genetic and/or environmental risk factors may in¯uence the development of melanoma in a kindred b a c CDKN2A mutations in familial melanoma JF Flores et al (histidine) in the ARF protein. The signi®cance of these latter ®ndings, if any, remains uncertain especially since the carriers of these mutations do not display any phenotypic features that distinguish them from other familial melanoma patients who have inherited mutations that do not aect the ARF protein this study) . The strongest evidence against the involvement of ARF in familial melanoma comes from our original analyses where we reported the identi®cation of ®ve independent mutations in exon 1a of the CDKN2A gene in our melanoma kindreds . These mutations would, predictably, have no eect on ARF since they reside within an exon that is not shared in common between the CDKN2A and ARF transcripts.
CDKN2B mutation screen
Mutations in exons 1 and 2 of the CDKN2B gene were screened for by SSCP in families where melanoma had not been found to segregate with a CDKN2A mutation (n=38). Methods were similar to those employed for the analysis of CDKN2A with the following primers: exon 1, forward primer=5'-CGTTAAGTTTACGGCCAACGG-3' and reverse primer=5'-ATCTAGGTTCCAGCCCCGAT-3'; exon 2, initial ampli®cation with primers 89F and 50R (Kamb et al., 1994a) followed by secondary amplifications with either (i) forward primer=5'-CACTCTGCTCTCTCTGGCAG-3' and reverse primer=5'-CACCAGCGTGTCCAGGAA-3' (5' region); (ii) forward primer=5'-CCCGACCGGTGCATGAT-3' and reverse primer=5'-AGGTACCCTGCAACGTCG-3' (mid region); or (iii) forward primer=5'-TGGACTTGGCCGAGGAG-3' and reverse pri- Eleven families that were assessed for transcriptional silencing of one CDKN2A allele by RT-PCR and direct sequencing. In brief, this involved extraction of RNAs from LCLs (RNeasy kits; Qiagen) which were then reverse transcribed with Superscript II reverse transcriptase (Gibco BRL) and ampli®ed (2 ml) with primers 305F and 530R (Hussussian et al., 1994) . A`touchdown' thermal cycling routine of 2 cycles at each degree between 658C and 568C, followed by 15 cycles at 558C, was used. Each cycle consisted of 45 seconds at 948C, 90 seconds at the annealing temperature and 90 seconds at 728C. Reactions (in duplicate) were electrophoresed on 1.5% agarose gels and bands were excised and puri®ed using a Qiagen gel extraction kit. Automated sequencing, using an Applied Biosystems Incorporated (ABI) Dye-Terminator cycle sequencing kit, was performed on both strands as previously described (Pollock et al., 1995) . Sequencing of LCL DNA from these patients, as well as`control' cDNAs which were derived from individuals known to be homozygous or heterozygous for these polymorphisms, was also performed to enable comparison of automated DNA sequencer traces. Those familes that harbored polymorphisms but were not analyzed further either carried a coding region mutation within CDKN2A or were homozygous for the polymorphism. b Eighteen families originally described in Walker et al., 1995. Re-evaluation of family 40929 indicated that inividuals within this kindred also carried the C to G polymorphism at nucleotide 500 (this study). The ten families indicated in bold-face type are ones in which melanoma cosegregates with a CDKN2A mutation 318 G>A 322 G>A Figure 2 Examples of SSCP shifts for exon 2 (mid region) of the CDKN2A gene. The two variant bands are indicative of the silent G to A substitution at nucleotide position 318 (codon V106) that was detected in 2/5 aected individuals in family 41015 (Table 2) , and the G to A mutation at nucleotide 322 (D108N) harbored by 2/4 aected individuals in family 41105 (Table 1 and Figure 1c) mer=5 . No SSCP variants were observed, indicating a lack of mutations or polymorphisms within CDKN2B in the individuals analysed. These ®ndings concur with those of others (Stone et al., 1995b; Platz et al., 1997) , where no mutations have been identi®ed in the coding region of this gene in other unrelated melanoma kindreds.
CDK4 mutation screen
Exon 2 of the CDK4 gene was screened by SSCP in 27 out of the 48 families that had not been previously screened for mutations in CDK4. This exon is the site of the only mutation (a C to T transition associated with the R24C substitution) that has been reported in familial, as well as sporadic, melanoma patients (WoÈ lfel et al., 1995; Zuo et al., 1996) . Since this mutation has been determined to create a novel StuI restriction enzyme site within the CDK4 gene (Zuo et al., 1996) , DNAs from aected members were also analysed non-isotopically via PCR ampli®cation of exon 2 followed by digestion of products with StuI.
DNA from a melanoma cell line (SK-MEL-28) known to harbor this particular mutation (unpublished results) served as a positive control in these assays. All 27 families were determined to be negative for the R24C CDK4 mutation. The identi®cation of this mutation is only 2/10 NIH families (Zuo et al., 1996) and in 0/48 of our Australian families suggests it contributes little to melanoma predisposition. To date, only 2% (2/86; includes 28 additional families from Fitzgerald et al., 1996) of all analysed melanoma kindreds have been found to carry this mutation.
Melanoma predisposition in Australia
Overall, only 10 out of 48 (21%) of our Australian melanoma families have been found to harbor CDKN2A mutations which cosegregate with melanoma. The possibility that susceptibility to melanoma in the remaining 38 families arises due to mutations in either the ARF product produced by the CDKN2A locus, CDK4, or CDKN2B, or, alternatively, is associated with an untranscribed CDKN2A allele, has also been ruled out in the current study. This leaves few explanations as to why the mutation frequency observed at CDKN2A is not higher; either the majority of these families inherit mutations within other, as yet unidenti®ed, melanoma susceptibility loci or melanoma has arisen in these families primarily due to shared environmental factors. The identi®cation of up to three sporadic cases of melanoma in 6 of our 10 families with CDKN2A mutations supports the latter conclusion and suggests that a number of our smaller families (with 4four aecteds and no evidence of a CDKN2A mutation) may just be clusters of sporadic melanoma cases. This speculation seems feasible given that the lifetime incidence of melanoma in Queensland, Australia (where all but one of our families come from) is approximately 7% (MacLennan et al., 1992) . In fact, we have observed during the course of our studies that the number of aected members in a family is as good a predictive indicator that a family will harbor a CDKN2A mutation as the sharing of a common 9p21 haplotype. Speci®cally, approximately half (8/18) of our largest families (with ®ve or more aected members) carry a CDKN2A mutation and, of those with mutations, a similar proportion (4/8; 50%) share a common 9p21 haplotype among all melanoma cases and this study) . In contrast, CDKN2A mutations were detected in only 2/30 of our smaller families (with 3 or 4 aecteds). Overall, these ®ndings suggest that the minimal number of aected cases used to designate a bona ®de Australian melanoma kindred should be raised to ®ve. Under this new restriction, the number of CDKN2A mutations observed in our families (8/18; 46%) approaches the mutational frequency of 58% (11/19) reported by Dracopoli and co-workers for CDKN2A mutations in NIH (or U.S.-based) melanoma kindreds (Hussussian et al., 1994; Dracopoli and Fountain, 1996) . The occurrence of melanoma in the remaining half or so of kindreds from both of these populations presumably arises due to the inheritance of a mutation in another melanoma predisposition locus, one of which (in the case of the NIH families) is CDK4.
